
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TGT-101
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Sponsor : mCureX
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's TGT-101 & CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
June 15, 2022
Lead Product(s) : TGT-101
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Sponsor : mCureX
Deal Size : Undisclosed
Deal Type : Collaboration
